372 related articles for article (PubMed ID: 16191241)
1. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
5. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
[TBL] [Abstract][Full Text] [Related]
6. Neurophysiological predictors of long term response to AChE inhibitors in AD patients.
Di Lazzaro V; Oliviero A; Pilato F; Saturno E; Dileone M; Marra C; Ghirlanda S; Ranieri F; Gainotti G; Tonali P
J Neurol Neurosurg Psychiatry; 2005 Aug; 76(8):1064-9. PubMed ID: 16024879
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Am J Alzheimers Dis Other Demen; 2003; 18(5):265-72. PubMed ID: 14569643
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Rozzini L; Chilovi BV; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
Am J Alzheimers Dis Other Demen; 2007; 22(1):42-7. PubMed ID: 17534001
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
10. [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years].
Lipczyńska-Łojkowska W; Ryglewicz D; Jedrzejczak T; Jakubowska T; Kotapka-Minc S; Sienkiewicz-Jarosz H; Bochyńska A
Neurol Neurochir Pol; 2004; 38(6):471-81. PubMed ID: 15654671
[TBL] [Abstract][Full Text] [Related]
11. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
Sharma T; Reed C; Aasen I; Kumari V
Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine in subcortical vascular dementia: an open 22-month study.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373
[TBL] [Abstract][Full Text] [Related]
13. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
14. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
16. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
[TBL] [Abstract][Full Text] [Related]
18. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
